In ABC DLBCL, the MYD88/CD79B double mutant shows an intense sensitivity to BTK inhibitors, while patients with mutated MyD88 but without BCR mutations (i.e., CD79A or CD79B) are not responsive [28,92]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.